Final results of the AIM study of ibrutinib and venetoclax in mantle cell lymphoma
Naveen Pemmaraju: what to look out for at ASH 2016
How can we overcome ibrutinib resistance?
Do CLL patients with mutated immunoglobulin receptors respond better to therapy?
Understanding the drivers behind disease with the 100,000 Genomes Project